DEXCOM, INC. vs WEST PHARMACEUTICAL SERVICES, INC., two Medical Devices stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where DXCM and WST diverge most: on debt / equity, DXCM reads 0.47 and WST reads 0.07; on fcf yield, DXCM reads 4.5% and WST reads 1.8%. The rest of the comparable metrics sit closer together. What WST's price implies is a somewhat stretched bet versus history (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | DXCM | WST |
|---|---|---|
| Price | $83.46 | $341.01 |
| Market cap | $31.5B | $24.3B |
| Sector | Medical Devices | Medical Devices |
| Stage | Growth | Mature |
| P/E | 33.1 | 43.7 |
| P/B | 12.01 | 8.13 |
| P/S | 6.34 | 7.31 |
| EV/EBITDA | 22.5 | 27.9 |
| Revenue growth | +15.7% | +12.5% |
| Gross margin | 63.4% | 37.7% |
| Operating margin | 24.3% | 20.5% |
| Net margin | 20.1% | 17.0% |
| Return on equity | 38.1% | 18.9% |
| Return on assets | 15.5% | 13.9% |
| Return on invested capital | 23.1% | 17.5% |
| FCF yield | 4.5% | 1.8% |
| Dividend yield | — | 0.3% |
| Debt / equity | 0.47 | 0.07 |
| Current ratio | 1.73 | 2.82 |
| Altman Z (solvency) | 6.81 | 8.89 |
| Piotroski F (quality) | 8 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.